Analyst Viewpoint
Increase in prevalence of neurological disorders is boosting the global neuroprotection market size. Rise in geriatric population, prevalence of stressful work environment, and growth in adoption of sedentary lifestyle are contributing to high cases of dementia, stroke, and Parkinson’s. Neuroprotection agents offer mechanisms to mitigate symptoms of neurodegenerative issues in an attempt to enhance patients’ quality of life and health.
Surge in healthcare investment is also augmenting the neuroprotection industry value. Growth in need for advanced critical care solutions has resulted in substantial investments in neuroprotection research. Prominent players operating in the global neuroprotection market are engaged in development of novel therapeutics and advancements in neural protection agents to expand their product portfolio and meet the rising demand worldwide.
Neuroprotection refers to a spectrum of strategies and interventions aimed to safeguard the structure and function of the nervous system, especially the brain, and preventing or slowing down the progression of neurodegenerative diseases. These interventions are vital in combating illnesses such as Alzheimer’s, Parkinson's, and stroke.
Neuroprotective agents can encompass pharmaceutical drugs and lifestyle modifications, all with the primary goal of mitigating neuronal damage. Symptoms of neurodegeneration include cognitive impairment such as memory loss, impaired judgment, and motor dysfunction such as muscle stiffness or slowed movement.
Benefits of using neuroprotective agents include improved patient outcomes, enhanced quality of life, and reduced burden to the national healthcare system associated with long-term critical care.
Recent neuroprotection market trends involve advancements in precision medicine, targeted drug delivery, and development of novel therapeutics.
Significant growth in prevalence of neurodegenerative illnesses such as Alzheimer’s and Parkinson’s can be ascribed to several factors such as rise in geriatric population, increase in pollution, and adoption of sedentary lifestyle.
As per a United Nations study, around 1 billion individuals, approximately one-sixth of the global population, are afflicted with neurological disorders. These conditions range from Alzheimer's and Parkinson's diseases to strokes, multiple sclerosis, epilepsy, and migraines.
The study further mentions that an estimated 6.8 million people succumb to these conditions per year. About 50 million individuals worldwide suffer from epilepsy, while more than 24 million live with symptoms of Alzheimer’s and other dementias. Around 2.5 million individuals globally suffer from multiple sclerosis, while Parkinson’s affects over 10 million people annually.
The neuroprotection industry consists of systems or agents that offer interventions via several mechanisms such as reduction of oxidative stress, inflammation, improvement of neuroplasticity, and rapid healing of damaged tissue.
Overall, these agents assist in mitigating ailments, slowing disease progression, and enhancing the quality of life of the patient, while reducing critical care costs. This is boosting neuroprotection market demand.
Increase in awareness about several chronic illnesses and the imperative need for advanced critical care solutions have led to an expansion in healthcare infrastructure and growth in investments in research.
Rise in the elderly population and life expectancy in general is leading to significant growth in patients suffering from Alzheimer’s, Parkinson’s, and strokes. This, in turn, is augmenting the funding required to address these healthcare challenges.
According to the Alzheimer’s Association, the institution invested US$ 100 Mn in dementia research in 2023. As per Alzheimer Disease International, the annual global cost of dementia stands at more than US$ 1.3 Trn and is expected to rise to US$ 2.8 Trn by 2030.
Investments in neuroprotection are pivotal to maintaining the nervous system’s health and mitigating degrading symptoms. Funds are directed toward innovative therapies, precision medicine methods, and drug discovery approaches or clinical trials, thereby fostering neuroprotection market opportunities for companies operating in the landscape.
North America accounted for the dominant neuroprotection market share in 2022. Surge in neurodegenerative disorders and increase in healthcare spending are augmenting the market dynamics of the region.
As per a report from the Alzheimer's Disease Association in 2022, nearly 6.2 million people in the U.S. suffer from Alzheimer’s disease. Similarly, according to the Parkinson’s Foundation, an estimated one million adults in the U.S. live with Parkinson’s disease. This number is likely to reach 1.2 million by 2030.
According to the latest neuroprotection market regional insights, the landscape in Asia Pacific appears promising owing to the region’s high-stress work culture and surge in geriatric population, which is prone to neurological issues.
Governments of several countries in Asia Pacific are working on improving their national healthcare infrastructure and accessibility to raise awareness about neurodegenerative illnesses such as dementia and Parkinson’s.
As per the latest neuroprotection market analysis, prominent manufacturers are investing substantially in the development of neuroprotective therapeutics and neuroprotective drugs to combat the prevalence of neurological issues.
Increase in focus on geographical expansion and improvement in product portfolio via close collaborations are key strategies followed by the leading players in the global landscape.
Daiichi Sankyo Company, Eli Lilly and Company, AbbVie Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc., Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, and Biogen Inc. are key firms operating in neuroprotection sector.
These companies have been profiled in the neuroprotection market research report based on parameters such as company overview, product portfolio, business strategies, financial overview, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 31.6 Bn |
| Market Forecast Value in 2031 | US$ 60.1 Bn |
| Growth Rate (CAGR) | 7.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 31.6 Bn in 2022
It is projected to grow at a CAGR of 7.5% from 2023 to 2031
Increase in prevalence of neurological disorders and surge in healthcare investment
The treatment segment accounted for the largest share in 2022
North America was the leading region in 2022
Daiichi Sankyo Company, Eli Lilly and Company, AbbVie Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc., Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, and Biogen Inc.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neuroprotection Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neuroprotection Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Neuroprotection Market Analysis and Forecast, By Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, By Product, 2017–2031
6.3.1. Free Radical Trapping Agents (Antioxidants)
6.3.2. Glutamate Antagonists (Anti-excitotoxic Agents)
6.3.3. Apoptosis Inhibitors
6.3.4. Anti-inflammatory Agents
6.3.5. Neurotrophic Factors (NTFs)
6.3.6. Metal Ion Chelators
6.3.7. Stimulants
6.3.8. Others
6.4. Market Attractiveness, By Product
7. Global Neuroprotection Market Analysis and Forecast, by Application
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Prevention
7.3.2. Treatment
7.4. Market Attractiveness, by Application
8. Global Neuroprotection Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Neuroprotection Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, By Product, 2017–2031
9.2.1. Free Radical Trapping Agents (Antioxidants)
9.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
9.2.3. Apoptosis Inhibitors
9.2.4. Anti-inflammatory Agents
9.2.5. Neurotrophic Factors (NTFs)
9.2.6. Metal Ion Chelators
9.2.7. Stimulants
9.2.8. Others
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Prevention
9.3.2. Treatment
9.4. Market Value Forecast, by Country, 2023–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country
10. Europe Neuroprotection Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, By Product, 2017–2031
10.2.1. Free Radical Trapping Agents (Antioxidants)
10.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
10.2.3. Apoptosis Inhibitors
10.2.4. Anti-inflammatory Agents
10.2.5. Neurotrophic Factors (NTFs)
10.2.6. Metal Ion Chelators
10.2.7. Stimulants
10.2.8. Others
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Prevention
10.3.2. Treatment
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country/Sub-region
11. Asia Pacific Neuroprotection Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, By Product, 2017–2031
11.2.1. Free Radical Trapping Agents (Antioxidants)
11.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
11.2.3. Apoptosis Inhibitors
11.2.4. Anti-inflammatory Agents
11.2.5. Neurotrophic Factors (NTFs)
11.2.6. Metal Ion Chelators
11.2.7. Stimulants
11.2.8. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Prevention
11.3.2. Treatment
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country/Sub-region
12. Latin America Neuroprotection Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, By Product, 2017–2031
12.2.1. Free Radical Trapping Agents (Antioxidants)
12.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
12.2.3. Apoptosis Inhibitors
12.2.4. Anti-inflammatory Agents
12.2.5. Neurotrophic Factors (NTFs)
12.2.6. Metal Ion Chelators
12.2.7. Stimulants
12.2.8. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Prevention
12.3.2. Treatment
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country/Sub-region
13. Middle East & Africa Neuroprotection Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, By Product, 2017–2031
13.2.1. Free Radical Trapping Agents (Antioxidants)
13.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
13.2.3. Apoptosis Inhibitors
13.2.4. Anti-inflammatory Agents
13.2.5. Neurotrophic Factors (NTFs)
13.2.6. Metal Ion Chelators
13.2.7. Stimulants
13.2.8. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Prevention
13.3.2. Treatment
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Application
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Daiichi Sankyo Company
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Treatment Type Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Eli Lilly and Company
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Treatment Type Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. AbbVie Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Treatment Type Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Dr. Reddy's Laboratories Ltd.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Treatment Type Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Treatment Type Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Novartis AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Treatment Type Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. AstraZeneca plc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Treatment Type Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Astrocyte Pharmaceuticals, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Treatment Type Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. F. Hoffmann-La Roche AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Treatment Type Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Biogen Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Treatment Type Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031
Table 02: Global Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Neuroprotection Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031
Table 05: North America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 06: North America Neuroprotection Market Value (US$ Mn) Forecast, by Country, 2023–2031
Table 07: Europe Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031
Table 08: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 09: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031
Table 11: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031
Table 14: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 15: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031
Table 17: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Neuroprotection Market Value Share Analysis, By Product 2022 and 2031
Figure 03: Global Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031
Figure 04: Global Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
Figure 05: Global Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031
Figure 06: Global Neuroprotection Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Neuroprotection Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031
Figure 09: North America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
Figure 10: North America Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031
Figure 11: North America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
Figure 12: North America Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031
Figure 13: North America Neuroprotection Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Neuroprotection Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: Europe Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
Figure 17: Europe Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031
Figure 18: Europe Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
Figure 19: Europe Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031
Figure 20: Europe Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Asia Pacific Neuroprotection Market Value Share Analysis, By Product 2022 and 2031
Figure 24: Asia Pacific Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031
Figure 25: Asia Pacific Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
Figure 26: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031
Figure 27: Asia Pacific Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Latin America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
Figure 31: Latin America Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031
Figure 32: Latin America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
Figure 33: Latin America Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031
Figure 34: Latin America Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Middle East & Africa Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031
Figure 38: Middle East & Africa Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031
Figure 39: Middle East & Africa Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031
Figure 40: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031
Figure 41: Middle East & Africa Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Neuroprotection Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Neuroprotection Market
